Gastroduodenal mucosal injury in patients on antiplatelet therapy

Thrombosis Research

Volumn 120, Issue 4, 2007, Pages 465-469

  Yamamoto, Takatsugu ^a   Sanaka, Masaki ^a   Nagasawa, Kunitaka ^a   Abe, Koichiro ^a   Fukami, Masako ^a   Nakayama, Shin ^a   Tsuchiya, Akihiko ^a   Ishii, Taro ^a   Kuyama, Yasushi ^a  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BACTERIUM ANTIBODY; BERAPROST; CILOSTAZOL; DIPYRIDAMOLE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; SARPOGRELATE; TICLOPIDINE; WARFARIN;

AGED; ANALYTIC METHOD; ARTICLE; CEREBROVASCULAR DISEASE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETES MELLITUS; DIGESTIVE SYSTEM INJURY; FEMALE; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL MUCOSA; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; MUCOSAL BLEEDING; MUCOSAL DISEASE; OUTPATIENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK; STATISTICAL SIGNIFICANCE; ULCER;

AGED; AGED, 80 AND OVER; DRUG THERAPY, COMBINATION; DUODENUM; ENDOSCOPY, GASTROINTESTINAL; FEMALE; GASTRIC MUCOSA; GASTROINTESTINAL DISEASES; HEMORRHAGE; HUMANS; INTESTINAL MUCOSA; JAPAN; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 34447651142     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2006.12.010     Document Type: Article

References (29)

1. Collaborative overview of randomized trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 308 (1994) 81-106
2. Steinhubl S.R., Berger P.B., Mann III J.T., Fry E.T., DeLago A., Wilmer C., et al. Clopidogrel for the reduction of events during observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288 (2002) 2411-2420
3. Chan A.W., Moliterno D.J., Berger P.B., Stone G.W., DiBattiste P.M., Yakubov S.L., et al. Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGIve Similar Efficacy Outcome Trial (TARGET). J Am Coll Cardiol 42 (2003) 1188-1195
4. Ahn J.C., Song W.H., Kwon J.A., Park C.G., Seo H.S., Oh D.J., et al. Effects of cilostazol on platelet activation in coronary stenting patients who already treated with aspirin and clopidogrel. Korean J Intern Med 19 (2004) 230-236
5. Schleinitz M.D., Olkin I., and Heidenreich P.A. Cilostazol, clopidogrel or ticlopidine to prevent sub-acute stent thrombosis: a meta-analysis of randomized trials. Am Heart J 148 (2004) 990-997
6. Diener H.C., Bogousslavsky J., Brass L.M., Cimminiello C., Csiba L., Kaste M., et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomized, double-blind, placebo-controlled trial. Lancet 364 (2004) 331-337
7. Lee S.W., Park S.W., Hong M.K., Kim Y.H., Lee B.K., Song J.M., et al. Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis. J Am Coll Cardiol 46 (2005) 1833-1837
8. Manolis A.S., Tzeis S., Andrikopoulos G., Koulouris S., and Melita H. Aspirin and clopidogrel: a sweeping combination in cardiology. Curr Med Chem Cardiovasc Hematol Agents 3 (2005) 203-219
9. McKevitt F.M., Randall M.S., Cleveland T.J., Gaines P.A., Tan K.T., and Venables G.S. The benefits of combined anti-platelet treatment in carotid artery stenting. Eur J Vasc Endovasc Surg 29 (2006) 522-527
10. Derry S., and Loke Y.K. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. Br Med J 321 (2000) 1183-1187
11. Sheikh R.A., Romano P.S., Prindiville T.P., Yasmeen S., and Trudeau W. Endoscopic evidence of mucosal injury in patients taking ticlopidine compared with patients taking aspirin/nonsteroidal anti-inflammatory drugs and controls. J Clin Gastroenterol 34 (2002) 529-532
12. Ibanez L., Vidal X., Vendrell L., Moretti U., Laporte J.R., and on behalf of the Spanish-Italian Collaborative Group for the Epidemiology of Gastrointestinal Bleeding. Upper gastrointestinal bleeding associated with antiplatelet drug. Aliment Pharmacol Ther 23 (2006) 235-242
13. Chan F.K., Ching J.Y., Hung L.C., Wong V.W., Leung V.K., Kung N.N., et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 352 (2005) 238-244
14. Quilliam B.J., Lapane K.L., Eaton C.B., and Mor V. Effect of antiplatelet and anticoagulant agents on risk of hospitalization for bleeding among a population of elderly nursing home stroke survivors. Stroke 32 (2001) 2299-2304
15. Buresly K., Eisenberg M.J., Zhang X., and Pilote L. Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction. Arch Intern Med 165 (2005) 784-789
16. Ng F.H., Wong B.C.Y., Wong S.Y., Chen W.H., and Chang C.M. Clopidogrel plus omeprazole compared with aspirin plus omeprazole for aspirin-induced symptomatic peptic ulcers/erosions with low to moderate bleeding/re-bleeding risk: a single-blind, randomized controlled study. Aliment Pharmacol Ther 19 (2004) 359-365
17. Fort F.T., Lafolie P., Toth E., and Lindgarde F. Gastroduodenal tolerance of 75 mg clopidogrel versus 325 mg aspirin in healthy volunteers: a gastroscopic study. Scand J Gastroenterol 35 (2000) 465-469
18. Woolf B. On estimating the relationship between blood group and disease. Ann Hum Genet 19 (1955) 251-253
19. Wargo K.A., Baty S.R., and Knowles G. Clopidogrel versus aspirin and esomeprazole to prevent recurrent bleeding. N Engl J Med 352 (2005) 1716-1718
20. Goto S. Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. Atheroscler Suppl 6 (2005) 3-11
21. Kwon S.U., Cho Y.J., Koo J.S., Bae H.J., Lee Y.S., Hong K.S., et al. Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke 36 (2005) 782-786
22. Douglas Jr. J.S., Holmes Jr. D.R., Kereiakes D.J., Grines C.L., Block E., Ghazzal A.M., et al. Coronary stent restenosis in patients treated with cilostazol. Circulation 112 (2005) 2826-2832
23. Iida O., Nanto S., Uematsu M., Morozumi T., Kotani J., Awata M., et al. Cilostazol reduces target lesion revascularization after percutaneous transluminal angioplasty in the femoropopliteal artery. Circ J 69 (2005) 1256-1259
24. Wilhite D.B., Comerota A.J., Schmieder F.A., Throm R.C., Gaughan J.P., and Rao A.K. Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time. J Vasc Surg 38 (2003) 710-713
25. Kim J.S., Lee K.S., Kim Y.I., Tamai Y., Nakahata R., and Takami H. A randomized crossover comparative study of aspirin, cilostazol and clopidogrel in normal controls: analysis with quantitative bleeding time and platelet aggregation test. J Clin Neurosci 11 (2004) 600-602
26. Chan F.K., Chung S.C., Suen B.Y., Lee Y.T., Leung W.K., Leung U.K., et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 344 (2001) 967-973
27. Lai K.C., Lam S.K., Chu K.M., Wong B.C., Hui W.M., Hu W.H., et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 346 (2002) 2033-2038
28. Liberopoulos E.N., Elisaf M.S., Tselepis A.D., Archimandritis A., Kiskinis D., Cokkinos D., et al. Upper gastrointestinal haemorrhage complicating antiplatelet treatment with aspirin and/or clopidogrel: where we are now?. Platelets 17 (2006) 1-6
29. Gurbel P.A., and Tantry U.S. Aspirin and clopidogrel resistance: consideration and management. J Interv Cardiol 19 (2006) 439-448